Chantal Mathieu (Belgium)
Professor of Internal Medicine Katholieke Universiteit Leuven, Belgium
Chantal Mathieu is Professor of Internal Medicine at the Katholieke Universiteit Leuven, Belgium. She is Chair of Endocrinology at the University Hospital Gasthuisberg Leuven. She received her Medical Degree and her PhD at the University of Leuven, where she subsequently completed training in internal medicine and endocrinology. Prof. Mathieu is Vice President and Chair Postgraduate Education of the EASD, as well as Chair of the European Diabetes Forum. She is a past associate editor and advisory board member of Diabetologia. She presently coordinates the INNODIA project on prevention and intervention in type 1 diabetes in Europe.

Moderator of 2 Sessions

 Conference Calendar

PLENARY 1 - PREVENTION AND CURE OF TYPE 1 DIABETES (Part 1)

Session Type
Plenary Session
Date
Thu, 28.04.2022
Session Time
08:10 - 08:55
Room
Hall 116
Chair(s)

Plenary Industry Symposium 01 (Not Included In The Main Event CME/CPD Credit)

Session Type
Industry Symposium
Date
Thu, 28.04.2022
Session Time
10:30 - 12:00
Room
Hall 116
Chair(s)
Session Description
The MiniMed™ 780G system: Expanding to the wider population with type 1 diabetes - Industry Symposium Supported by Medtronic International Trading Sarl

Session Description:

Innovation of technology in type 1 diabetes has transformed the therapy and significantly improved both clinical and patient related outcomes. This symposium, chaired by Prof. Chantal Mathieu, will focus on extending the use of the MiniMed™ 780G system to the wider population of people with type 1 diabetes, in terms of clinical outcomes, patient related outcomes, and economic value. The results of three studies evaluating the MiniMed™ 780G system will be presented for the first time: Prof. Pratik Choudhary will discuss the transition of people not achieving the treatment goals with MDI and isCGM, followed by Prof. Tomasz Klupa who will address the transition of those totally naïve to pump or CGM technologies. The use of the MiniMed™ 780G system with Fiasp in the adolescent population during exercise, will be further discussed by Dr. Klemen Dovc.

Lastly, Prof. Ohad Cohen, Medical Director of Medtronic, will summarize the data presented and its implications on successfully achieving goals in growing populations and indications of people with type 1 diabetes.

Presenter of 3 Presentations

 Conference Calendar

Questions & answers

Session Name
0170 - Plenary Industry Symposium 01 (Not Included In The Main Event CME/CPD Credit) (ID 9)
Session Type
Industry Symposium
Date
Thu, 28.04.2022
Session Time
10:30 - 12:00
Room
Hall 116
Presenter
Lecture Time
11:44 - 12:00

The Current State of Type 1 Diabetes

Session Name
0170 - Plenary Industry Symposium 01 (Not Included In The Main Event CME/CPD Credit) (ID 9)
Session Type
Industry Symposium
Date
Thu, 28.04.2022
Session Time
10:30 - 12:00
Room
Hall 116
Presenter
Lecture Time
10:30 - 10:40

Can we arrest type 1 diabetes?

Session Name
0120 - PLENARY 1 - PREVENTION AND CURE OF TYPE 1 DIABETES (Part 1) (ID 62)
Session Type
Plenary Session
Date
Thu, 28.04.2022
Session Time
08:10 - 08:55
Room
Hall 116
Presenter
Lecture Time
08:30 - 08:50

Abstract

Abstract Body

After 100 years of insulin therapy, our insights in the pathogenesis of type 1 diabetes (T1D) have evolved and using the combination of genetic risk and presence of autoantibodies in the blood has allowed us to progress in the prediction of risk. Consortia worldwide are exploring the value of novel biomarkers and evaluate interventions targeting arresting progression of beta-cell destruction in people with newly diagnosed T1D or in those at risk of T1D. In Europe, the IMI2-funded projects INNODIA and INNODIA HARVEST focus on novel biomarker discovery and the consortium is executing 4 clinical trials in people with newly diagnosed T1D. An overview of activities, as well as the evolution of novel therapies for prevention and arrest of T1D will be discussed.

Hide